Paragon Pharmacies Limited
TSX VENTURE : PGN

Paragon Pharmacies Limited

November 19, 2010 17:56 ET

Paragon Pharmacies Limited Appoints Kristal Kaye as Chief Financial Officer

KELOWNA, BRITISH COLUMBIA--(Marketwire - Nov. 19, 2010) - Paragon Pharmacies Limited ("Paragon" or "the Company") (TSX VENTURE:PGN) today announced the appointment of Kristal Kaye, MBA, CGA, as the Company's Chief Financial Officer. Ms. Kaye's appointment is effective Monday, November 22, 2010.

Ms. Kaye joined the Company in July 2008 as Corporate Controller and she was subsequently appointed Director of Finance and Administration in August 2009. In her capacity as Chief Financial Officer, Ms. Kaye will continue to oversee and direct Paragon's financial management, information technology and business processes.

"Kristal brings a wealth of experience to her role and is a pivotal member of the senior management team," said R. Gordon Gooding, Chief Executive Officer. "She has been one of the major contributors in enabling the Company to move forward with its various initiatives including strategic planning. Her strong background in leadership, financial analysis, operations, management and business planning and the significant time spent in both public and private business environments, will continue to be a valuable asset to Paragon."

Ms. Kaye earned her CGA in 2004 and her MBA in 2006.

Paragon Pharmacies Limited is building a pharmacy with our customers in mind. Headquartered in Kelowna, BC and employing over 400 staff, Paragon currently owns and operates 19 retail pharmacies and three central fill pharmacies throughout British Columbia, Alberta and Manitoba. Paragon is a leading mid-market pharmacy, providing premier pharmacy services in a friendly, community-focused environment.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements regarding, among other things, the Company's beliefs, plans, objectives, strategies, estimates, intentions and expectations, including as they relate to its operating and financial results, capital expenditures and the ability to execute on its operating, investing and financing strategies. Consequently, actual results and events may differ materially from those included in, contemplated or implied by such forward looking statements for a variety of reasons. Forward-looking statements are subject to inherent risks and uncertainties including, but not limited to, market and general economic conditions, certain property and casualty risks, the ability to attract and retain pharmacists, the availability and terms of financing, changes in the Company's relationship with its key suppliers, competitive factors, changes in regulatory environments affecting the Company's business, and the accuracy in management's assumptions (see "RISKS AND RISK MANAGEMENT" as noted in the Company's Management's Discussion & Analysis posted on SEDAR at www.sedar.com). This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. Investors and others should carefully consider these and other factors and not place undue reliance on these forward-looking statements. In addition, these forward-looking statements relate to the date on which they were made and the Company disclaims and has no intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Paragon Pharmacies Limited
    R. Gordon Gooding, CA
    Chief Executive Officer
    (250) 868-8400
    (250) 868-8402 (FAX)
    www.helloparagon.com